Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-line treatment for patients with Undifferentiated Pleomorphic Sarcoma
Investigators conducted a single-arm, phase Ib trial to determine the safety and preliminary efficacy of epirubicin (a chemotherapy that forms a complex with DNA and interrupts DNA replication), ifosfamide (a chemotherapy that works by damaging DNA and inhibiting cell replication), and nivolumab (a PD-1 receptor inhibitor as mentioned above) as first-line treatment for advanced Undifferentiated Pleomorphic Sarcoma (UPS). Only adult patients with a confirmed UPS diagnosis were eligible.
Sixteen patients were enrolled and a phase II recommended dose was determined. A preliminary objective response rate was 68.8% with a median progression free survival of 9.9 months. These results are quite early; however, the data indicate the combination of epirubicin,
ifosfamide, and nivolumab is a safe and may be effective the treatment of advanced UPS.
Read the full study in Clinical Cancer Research.